GREY:BTGGF - Post Discussion
Post by
StokkerPro on Aug 10, 2018 2:40pm
BTG Issued with Rejection Confirmation for Elevair Coils
The US Food & Drug Administration has rejected a premarket application by BTG PLC for Elevair Endobronchial Coil system. Elevair is currently under development for treatment of a type of lung condition called emphysema. Shares responded with a slump. Following the announcement on Thursday, BTG shares dropped 2.8% to trade at 510.50 pence in the morning hours. The company is marketing Elevair in the EU under the brand name PneumRx Coils. It is a coil that is carefully implanted into the lungs of a person suffering from emphysema. The coil is used to keep the airways open when the patient breathes out. This is intended to prevent the airways from collapsing. The device works by reducing lung volume. Read more:
https://marketexclusive.com/btg-issued-with-rejection-confirmation-for-elevair-coil-system-by-the-fda/2018/08/
Be the first to comment on this post